News | January 18, 2024
Venus Remedies eceives GMP certification from Libya
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
The certification underscores Venus Remedies Limited's adherence to stringent quality control measures
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Marks remarkable acceleration in innovation using AI technology
Furthering cell therapy ambition across oncology and autoimmune diseases
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
Clariant Healthcare highlighted Vitipure Meglumine LEX and VitiPure Superior at the recently concluded CPhI India
The new ECO grade is made using renewable feedstock
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Subscribe To Our Newsletter & Stay Updated
